Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Princess Maxima Center for Pediatric Oncology
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07156435CT.gov Vyxeos® With Clofarabine for Pediatric AML | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vyxeos (this asset) | Princess Maxima Center for Pediatric Oncology | P1 | CC · 43 |
| Etoposide | Joanna Yi | P3 | BBB |
| Cytarabine | Children's Oncology Group | P3 | BBB |
| Nivestim | National Cancer Institute (NCI) | P3 | BBB |
| Methotrexate | Children's Oncology Group | P3 | BBB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BBB |
| Fludarabine | National Cancer Institute (NCI) | P3 | BB |
| Romidepsin | Washington University School of Medicine | P3 | BB |
| Cyclosporin A | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P3 | BB |
+42 more in the Childhood Acute Myeloid Leukemia cohort
Other indications for Vyxeos
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myelodysplastic Syndrome | — | P2/3 | B · 57 |
| Acute Myeloid Leukemia | — | P2/3 | B · 56 |
| Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vyxeos in Childhood Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vyxeos-childhood-acute-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →